Sanofi is following in the footsteps of ... said the pharma group. The range of consumer healthcare products it offers will also be “streamlined” ahead of the spin-off. According to the ...
Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...
After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...
Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...
in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large stake in its consumer health unit. The sale of Sanofi's controlling ...
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
Hosted on MSN24d
Sanofi Down 10% in 3 Months: How Should You Play the Stock?Sanofi’s SNY stock has declined 10.2% in ... The EPS estimate has declined to exclude costs related to its Consumer Healthcare (CHC) unit, which the company plans to separate through the ...
Sanofi (NASDAQ:SNY – Get Free Report) has been given a consensus recommendation of “Buy” by the three brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback